Allergan acquires rights to Ironwood's Constella from Almirall in more than 40 countries

Transaction includes the European Union, Switzerland, Turkey and the Commonwealth of Independent States.

Under the terms of the agreement, Allergan acquired an exclusive license for Constella in these countries. The license agreement includes the development and commercialization of Constella for the treatment of irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and other gastrointestinal (GI) conditions. Constella is currently approved by the European Commission for the symptomatic treatment of moderate-to-severe IBS-C in adults.

"The acquisition of rights for Constella in these international markets is the next step towards our goal of becoming an even stronger partner for physicians globally seeking innovative therapies for their patients suffering from gastrointestinal disorders," said Paul Navarre, EVP and President of International Brands at Allergan. "This agreement allows us to add Constella to our existing GI portfolio in select countries internationally and paves the way for future GI treatments in our own pipeline."

"Constella is the only prescription product approved for IBS-C patients in Europe, providing them with a treatment option that can improve symptoms such as abdominal pain, bloating and constipation which are associated with this disorder," said Tom McCourt, Chief Commercial Officer of Ironwood. "With Allergan's strong global commercial presence, including experience in Europe commercializing both specialty and primary care brands, we look forward to their efforts to bring Constella to adult IBS-C patients internationally."